Indication: Metastatic Breast Cancer

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS–8201A), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Pretreated with HER2 Therapies

Sub-indication: Metastatic/ unresectable, HER2 positive prewviously treated with T-DM1 (2nd line)

Line of Therapy: metastatic/unresectable HER2 positive- 2nd line (previously treated with T-DM1)

Drug Study

Principal Investigator: Jeffrey Hargis, M.D.
Norton Cancer Institute

Sponsor: Daiichi Sankyo Company, Limited

Learn more at ClinicalTrials.gov

Email for more information: Breast-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.